

In the Claims:

A complete listing of the claims proper claim identifiers is set forth below.

Claim 1 (**Previously Presented**). A method for enhancing the bioavailability of orally administered ospemifene or a pharmaceutically acceptable salt thereof, comprising orally administering the ospemifene or pharmaceutically acceptable salt thereof, to an individual in connection with the intake of a foodstuff having nutritional value and causing secretion of bile acids, wherein said ospemifene or pharmaceutically acceptable salt thereof is administered at a time point which is in the range defined by 1 hour before starting the food intake and 2 hours after starting the food intake to enhance bioavailability of the ospemifene or pharmaceutically acceptable salt thereof.

Claims 2 and 3 (**Canceled**).

Claim 4 (**Previously Presented**). The method according to claim 1 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered within one hour after the food intake was started.

Claim 5 (**Previously Presented**). The method according to claim 4 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered at a time point which is no later than 0.5 hour after starting the food intake.

Claim 6 (**Canceled**).

Claim 7 (**Previously Presented**). The method according to claim 1 wherein the ospemifene or pharmaceutically acceptable salt thereof is used for treatment of osteoporosis and the individual is in need of treatment for osteoporosis.

Claim 8 (**Previously Presented**). The method according to claim 1 wherein the

ospemifene or pharmaceutically acceptable salt thereof is used for treatment of symptoms related to skin atrophy, or to epithelial or mucosal atrophy and the compound is administered to a patient in need of treatment of symptoms related to skin atrophy, or to epithelial or mucosal atrophy.

Claim 9 (Original). The method according to claim 8 wherein the symptoms related to atrophy are urinary symptoms or vaginal symptoms.

Claim 10 (Previously Presented). The method according to claim 7, wherein the ospemifene or pharmaceutically acceptable salt thereof is administered in oral dosage form and wherein the dosage amount is from 30 to 90 mg/day.

Claim 11 (Previously Presented). The method according to claim 10, wherein the dosage amount is 60 mg.

Claim 12 (Previously Presented). The method according to claim 8, wherein the ospemifene, or pharmaceutically acceptable salt thereof, is administered in oral dosage form and wherein the dosage amount is from 30 to 90 mg/day.

Claim 13 (Previously Presented). The method according to claim 12, wherein the dosage amount is 60 mg.

Claim 14 (Previously Presented). A method for enhancing the bioavailability of orally administered ospemifene comprising orally administering the ospemifene to an individual in connection with the intake of a foodstuff having nutritional value and causing secretion of bile acids, wherein said ospemifene is administered at a time point which is in the range defined by 1 hour before starting the food intake and 2 hours after starting the food intake to enhance bioavailability of the ospemifene.

Claim 15 (Previously Presented). The method according to claim 14, wherein the ospemifene is used for treatment of symptoms related to skin atrophy, or to epithelial or mucosal atrophy and the ospemifene is administered to an individual in need of treatment of symptoms related to skin atrophy, or to epithelial or mucosal atrophy.

Claim 16 (Previously Presented). The method according to claim 15, wherein the ospemifene is administered in oral dosage form and wherein the dosage amount is from 30 to 90 mg/day.

Claim 17 (Previously Presented). The method according to claim 16, wherein the dosage amount is 60 mg.

Claim 18 (Previously Presented). The method according to claim 14, wherein the compound is used for treatment of osteoporosis and the ospemifene is administered to an individual in need of treatment for osteoporosis.

Claim 19 (Previously Presented). The method according to claim 18, wherein the ospemifene is administered in oral dosage form and wherein the dosage amount is from 30 to 90 mg/day.

Claim 20 (Previously Presented). The method according to claim 19, wherein the dosage amount is 60 mg.

Claim 21 (Previously Presented). A method of inhibiting urogenital atrophy comprising orally administering a therapeutically effective amount of ospemifene or a pharmaceutically acceptable salt thereof to a patient in need thereof in connection with the intake of a foodstuff having nutritional value and causing secretion of bile acids, wherein said ospemifene or pharmaceutically acceptable salt thereof is administered at a time point which is in the range defined by 1 hour before starting the food intake and 2

hours after starting the food intake to enhance bioavailability of the ospemifene or pharmaceutically acceptable salt thereof.

Claim 22 (**Canceled**).

Claim 23 (**Previously Presented**). The method according to claim 21 wherein the ospemifene or pharmaceutically acceptable salt thereof is administered in oral dosage form and wherein the dosage amount is from 30 to 90 mg/day.

Claim 24 (**Previously Presented**). The method according to claim 23 wherein the dosage amount is 60 mg.